SEC Filing Summary: Prima Biomed Ltd (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by Prima Biomed Ltd, a foreign private issuer headquartered in Sydney, Australia, on November 24, 2017. The filing serves as a report pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934. The registrant files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a disclosure of director interest notices rather than a financial results report.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this filing. The document focuses on regulatory compliance regarding director holdings.
Guidance, Outlook, and Disclosures
The filing contains no management commentary, financial guidance, or outlook. The primary content consists of the following exhibits:
- Exhibit 99.1: Appendix 3Z, Final Director's Interest Notice for Mr. Albert Wong.
- Exhibit 99.2: Appendix 3Z, Final Director's Interest Notice for Ms. Lucy Turnbull.
The report was signed by Marc Voigt, Chief Executive Officer.
Key Facts for Investor Verification
- Verify the specific shareholding details for Directors Albert Wong and Lucy Turnbull in the referenced Appendix 3Z notices.
- Confirm the company's current financial status by reviewing the most recent Form 20-F or quarterly reports, as this filing contains no financial data.
- Note the registrant's name is Prima Biomed Ltd, distinct from the metadata reference to "IMMUTEP Ltd."